Compass Therapeutics Provides Corporate Update
BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported a business update.
Related news for (CMPX)
- MoBot’s Stock Market Highlights – 08/11/25 02:00 PM
- Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
- 24/7 Market News Snapshot 11 August, 2025 – Compass Therapeutics, Inc. Common Stock (NASDAQ:CMPX)
- Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
- Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting